Daily Endocrinology Research Analysis
Three impactful endocrinology-related studies stood out: a massive gene–sleep interaction meta-analysis identified novel lipid loci and implicated vitamin D receptor signaling; a prospective cohort showed CUN‑BAE effectively predicts MASLD risk in non‑obese adults with partial mediation by TyG; and a nationwide Medicare cohort found CGM use in insulin‑treated older adults with ADRD was associated with lower hospitalization and mortality than SMBG.
Summary
Three impactful endocrinology-related studies stood out: a massive gene–sleep interaction meta-analysis identified novel lipid loci and implicated vitamin D receptor signaling; a prospective cohort showed CUN‑BAE effectively predicts MASLD risk in non‑obese adults with partial mediation by TyG; and a nationwide Medicare cohort found CGM use in insulin‑treated older adults with ADRD was associated with lower hospitalization and mortality than SMBG.
Research Themes
- Gene–environment interactions linking sleep and lipid metabolism
- Risk stratification for MASLD in non-obese populations
- Diabetes technology outcomes in cognitively impaired older adults
Selected Articles
1. Genome-wide gene-sleep interaction study identifies novel lipid loci in 732,564 participants.
Across 732,564 participants from 55 cohorts, genome-wide interaction meta-analyses identified 17 loci where genetic effects on lipids depend on short or long sleep. The results implicate vitamin D receptor–related signaling in sleep-associated lipid perturbations, suggesting new mechanistic targets for dyslipidemia among individuals with atypical sleep duration.
Impact: This is one of the largest gene–environment interaction studies in lipid biology, uncovering sleep-sensitive lipid loci and pointing to druggable pathways such as the vitamin D receptor pathway.
Clinical Implications: While immediate clinical practice change is premature, the identified loci and implicated pathways could guide precision prevention or therapeutics for dyslipidemia in patients with short/long sleep. It also supports integrating sleep assessment into cardiometabolic risk profiling.
Key Findings
- Meta-analyses across 55 cohorts (N=732,564) identified 17 sleep-sensitive lipid loci (9 with short sleep, 8 with long sleep).
- One-degree-of-freedom interaction tests detected 10 novel loci beyond main-effect signals.
- Findings implicate vitamin D receptor–related pathways in sleep-associated lipid changes, highlighting potential therapeutic targets.
Methodological Strengths
- Very large, multi-cohort genome-wide interaction meta-analysis with standardized sleep definitions.
- Applied both 1-df interaction and 2-df joint tests to capture interaction and main effects robustly.
Limitations
- Sleep duration was derived from cohort-specific standardized self-report, which may introduce measurement error.
- Predominantly European ancestry (87%) limits generalizability; functional validation of implicated pathways is needed.
Future Directions: Functional validation of the identified loci, cross-ancestry replication, and interventional studies targeting implicated pathways (e.g., vitamin D receptor signaling) in individuals with short/long sleep.
BACKGROUND AND AIMS: Deviations from the population mean in sleep duration have been associated with increased risk for developing dyslipidemia and atherosclerotic cardiovascular disease, but the mechanism of effect is poorly characterized. We performed large-scale genome-wide gene-sleep interaction analyses of lipid levels to identify genetic variants underpinning the biomolecular pathways of sleep-associated lipid disturbances and to suggest possible druggable targets. METHODS: We collected data from 55 cohorts with a combined sample size of 732,564 participants (87 % European ancestry) with data on lipid traits (high-density lipoprotein [HDL-c] and low-density lipoprotein [LDL-c] cholesterol and triglycerides [TG]). Short (STST) and long (LTST) total sleep time were defined by the extreme 20 % of the age- and sex-standardized values within each cohort. Based on cohort-level summary statistics data, we performed meta-analyses for one-degree of freedom tests of interaction and two-degree of freedom joint tests of the SNP-main and -interaction effect on lipid levels. RESULTS: The one-degree of freedom variant-sleep interaction test identified 10 novel loci (P CONCLUSIONS: Collectively, the 17 (9 with short and 8 with long sleep) loci provided evidence into the biomolecular mechanisms underlying sleep-associated lipid changes, including potential involvement of the vitamin D receptor pathway. Collectively, these findings may contribute developing novel interventions for treating dyslipidemia in people with sleep disturbances.
2. CUN‑BAE predicts risk of metabolic dysfunction-associated steatotic liver disease: A prospective cohort study in non‑obese Chinese adults.
In 16,173 non-obese Chinese adults followed for 5 years, higher CUN‑BAE strongly predicted incident MASLD with clear dose–response and sex-specific patterns. The TyG index mediated 24.7% of the CUN‑BAE–MASLD link, indicating insulin resistance is important but not the sole pathway.
Impact: Identifies a practical adiposity estimator that outperforms BMI for MASLD risk in non-obese individuals, a growing and often overlooked group.
Clinical Implications: CUN‑BAE can be incorporated into primary care risk assessment to identify non-obese adults at high MASLD risk, prompting liver ultrasound, lifestyle counseling, and metabolic optimization even when BMI is normal.
Key Findings
- Each 1-SD increase in CUN‑BAE associated with 35% higher MASLD risk (HR 1.35, 95% CI 1.29–1.41).
- Top vs bottom CUN‑BAE tertile had HR 1.95 for incident MASLD; 5-year cumulative incidence 8.4% (lowest), 15.8% (middle), 18.9% (highest).
- TyG index mediated 24.7% of the CUN‑BAE–MASLD association; women showed a sharp risk rise above CUN‑BAE ~31.2.
Methodological Strengths
- Large prospective cohort with 5-year follow-up and rigorous multivariable adjustment.
- Use of restricted cubic splines, sex-stratification, and structural equation modeling for mediation.
Limitations
- MASLD diagnosis based on ultrasonography may miss mild steatosis; single-country cohort limits generalizability.
- Observational design cannot establish causality; unmeasured confounding is possible.
Future Directions: External validation across ancestries, head-to-head comparison with other non-invasive indices, and interventional studies to test whether CUN‑BAE–guided screening improves MASLD outcomes.
While metabolic dysfunction-associated steatotic liver disease (MASLD) increasingly affects non-obese individuals, current screening approaches show poor performance in this population. We investigated whether the Clínica Universidad de Navarra-Body Adiposity Estimator (CUN-BAE) could better identify MASLD risk than traditional measures in non-obese adults, and examined how the triglyceride-glucose (TyG) index might mediate this relationship. Using data from the Dryad public database, we followed 16,173 Chinese non-obese adults (BMI < 25 kg/m²) without baseline MASLD for 5 years. MASLD diagnosis relied on abdominal ultrasonography. We applied multivariable logistic regression to assess cross-sectional associations and Cox models for incident disease risk. Restricted cubic splines revealed dose-response patterns in sex-stratified analyses, while structural equation modeling quantified TyG index mediation effects. Our cohort included 8,483 men and 7,690 women. After full adjustment, each standard deviation increased in CUN-BAE linked to 35% higher MASLD risk (HR = 1.35, 95% CI: 1.29-1.41, P < 0.001). Comparing top versus bottom tertiles showed 95% increased risk (HR = 1.95, 95% CI: 1.74-2.18, P < 0.001). Five-year cumulative incidence rose from 8.4% (lowest tertile) to 15.8% (middle) to 18.9% (highest tertile, Log-rank P < 0.0001). Cubic spline analysis uncovered sex differences: women showed a sharp risk increase above CUN-BAE 31.2, while men displayed more gradual, linear patterns. The TyG index accounted for 24.7% of the CUN-BAE-MASLD association (P < 0.001). CUN-BAE effectively predicts MASLD development in Chinese non-obese adults through clear dose-response relationships that differ by sex. Since TyG index only partially explains this association, insulin resistance appears important but insufficient to account for the full relationship. CUN-BAE could serve as a practical screening tool to identify high-risk individuals missed by conventional BMI-based approaches, enabling more precise risk stratification in non-obese populations.
3. Continuous Glucose Monitoring in Insulin-Treated Older Adults With Diabetes and Alzheimer Disease and Related Dementias.
In 2,022 matched Medicare beneficiaries aged ≥66 years with ADRD on insulin, therapeutic CGM use was associated with lower all-cause hospitalization (HR 0.86) and mortality (HR 0.57) compared with prevalent SMBG. Trends for fewer hypoglycemia hospitalizations and falls were not statistically significant; a negative control outcome showed no difference.
Impact: Addresses a vulnerable, understudied group—older adults with cognitive impairment—showing real-world associations between CGM use and hard outcomes.
Clinical Implications: Clinicians should consider CGM for insulin-treated older adults with ADRD, balancing caregiver support and safety, and advocate for pragmatic trials to confirm effectiveness and feasibility in this population.
Key Findings
- CGM vs SMBG was associated with lower all-cause hospitalization (HR 0.86; 95% CI 0.76–0.96).
- All-cause mortality was markedly lower with CGM (HR 0.57; 95% CI 0.48–0.67).
- Non-significant trends favored CGM for hypoglycemia hospitalization and falls; negative control outcome showed no difference.
Methodological Strengths
- Nationwide Medicare dataset with prevalent-new user design and 1:1 propensity score matching.
- Use of negative control outcome and Cox models to strengthen causal inference.
Limitations
- Observational design with potential residual confounding and selection bias.
- CGM users may differ in unmeasured factors (care support, technology adoption) influencing outcomes.
Future Directions: Pragmatic randomized or cluster trials of CGM in ADRD populations, evaluation of caregiver-mediated CGM workflows, and cost-effectiveness analyses.
IMPORTANCE: Cognitive impairment and glycemic control have a bidirectional association. Understanding the impact of continuous glucose monitoring (CGM) vs self-monitoring of blood glucose (SMBG) is important for treating older adults with Alzheimer disease and related dementias (ADRD) and diabetes that is treated with insulin. OBJECTIVE: To compare the risks of glycemic outcomes and related adverse events between CGM users and prevalent SMBG users in insulin-treated older adults with ADRD and diabetes. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, prevalent-new user cohort study utilized a nationwide, 15% random sample of Medicare claims data (Parts A, B, and D) from January 2016 to December 2020 to ensure balanced cohorts. Insulin-treated older adults (≥66 years) with ADRD and diabetes were included. Individuals in hospice care or with a professional CGM use were excluded. Analysis was carried out from August 2023 to December 2024. EXPOSURE: Therapeutic CGM use vs prevalent SMBG use. MAIN OUTCOMES AND MEASURES: Primary outcomes included hypoglycemia hospitalizations, hyperglycemia crisis, and all-cause mortality; falls and all-cause hospitalizations were secondary outcomes. Upper respiratory tract infections served as a negative control outcome. A 1:1 propensity score matching with a 0.25 caliper was carried out for confounding control. Cox proportional hazards models were used for outcome analysis. RESULTS: In this cohort of 2022 insulin-treated older adults with diabetes and ADRD (1011 CGM users and 1011 SMBG users; mean [SD] age, 76.4 [6.7] years; 1133 female [56.0%]), CGM use was significantly associated with lower risk of all-cause hospitalization (hazard ratio [HR], 0.86; 95% CI, 0.76-0.96) and mortality (HR, 0.57; 95% CI, 0.48-0.67) compared with SMBG use. CGM use had lower point estimates for hypoglycemia hospitalization (HR, 0.66; 95% CI, 0.40-1.08) and falls (HR, 0.86; 95% CI, 0.68-1.08) and higher point estimates for hyperglycemia crisis (HR, 1.38; 95% CI, 0.99-1.94) vs SMBG use, but these findings were not significant. Exploratory subgroup analyses showed varied benefits. The negative control outcome showed no significant differences across analyses. CONCLUSIONS AND RELEVANCE: In this cohort study of insulin-treated older adults with ADRD and diabetes, CGM use was associated with improved long-term clinical outcomes. Pragmatic (ie, evaluating the effectiveness of healthcare interventions in everyday settings) trials are needed to validate these findings and to assess the feasibility of CGM use in this population.